We recently compiled a list of the 12 Cheapest Stocks with Biggest Upside Potential. In this article, we are going to take a ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will ...

The acquisition of IDRx will help GSK target a ‘major gap in the current standard of care’ related to gastrointestinal ...

Under the agreement, GSK will pay $1billion upfront to acquire the Massachussetts-based firm, followed by up to $150million ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...

IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal tumours.

UK-based drug maker GSK stated that it is going to acquire US biopharmaceutical firm IDRx for up to USD1.15 billion. The Boston ...

British medicine producer GSK on Monday noted that it is going to purchase US biopharmaceutical firm IDRx for up to USD1.15 billion. The Boston-originated biotechnology company is producing ...

(Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its ...

A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...